Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
August 13 2007 - 1:59PM
PR Newswire (US)
THE WOODLANDS, Texas, Aug. 13 /PRNewswire-FirstCall/ -- Lexicon
Pharmaceuticals, Inc. (NASDAQ:LXRX) today announced the company
will be making an oral presentation at the American Chemical
Society National Meeting and Exposition in Boston, Massachusetts on
Tuesday, August 21, 2007 at 2:50 p.m. Eastern Time. The
presentation, based on the paper titled, "Modulation of peripheral
serotonin levels by enzyme inhibitors for the potential treatment
of irritable bowel syndrome (IBS)," will reveal the target of
Lexicon's clinical candidate, LX1031, a potential treatment for
irritable bowel syndrome (IBS), which is currently being
investigated in a Phase 1b clinical trial in healthy volunteers.
The presentation is part of the Division of Medicinal Chemistry
general oral session and the paper number is 235. Lexicon will also
present a separate poster titled, "Open access mass-directed
purification: Adaptation to diverse loading scales and compound
polarities," at the same conference on August 19, 2007. The paper
number is 174 and will be included in the Division of Medicinal
Chemistry poster session which begins at 7:00 p.m. Eastern Time.
About Lexicon Lexicon is a biopharmaceutical company focused on the
discovery and development of breakthrough treatments for human
disease. Lexicon currently has development programs underway for
such areas of major unmet medical need as irritable bowel syndrome
and cognitive disorders. The company has used its proprietary gene
knockout technology to discover more than 100 promising drug
targets and create an extensive pipeline of clinical and
preclinical programs in the therapeutic areas of diabetes and
obesity, cardiovascular disease, psychiatric and neurological
disorders, cancer, immune system disorders and ophthalmic disease.
To advance the development and commercialization of its programs,
Lexicon is working both independently and through collaborators
including Bristol-Myers Squibb Company, Genentech, Inc. and N.V.
Organon. For additional information about Lexicon and its programs,
please visit http://www.lexpharma.com/. Safe Harbor Statement This
press release contains "forward-looking statements," including
statements relating to Lexicon's clinical development of LX1031 and
the potential therapeutic and commercial potential of LX1031. This
press release also contains forward-looking statements relating to
Lexicon's growth and future operating results, discovery and
development of products, strategic alliances and intellectual
property, as well as other matters that are not historical facts or
information. All forward-looking statements are based on
management's current assumptions and expectations and involve
risks, uncertainties and other important factors, specifically
including those relating to Lexicon's ability to successfully
conduct clinical development of LX1031 and preclinical and clinical
development of its other potential drug candidates, advance
additional candidates into preclinical and clinical development,
obtain necessary regulatory approvals, achieve its operational
objectives, obtain patent protection for its discoveries and
establish strategic alliances, as well as additional factors
relating to manufacturing, intellectual property rights, and the
therapeutic or commercial value of its drug candidates, that may
cause Lexicon's actual results to be materially different from any
future results expressed or implied by such forward-looking
statements. Information identifying such important factors is
contained under "Factors Affecting Forward-Looking Statements" and
"Risk Factors" in Lexicon's annual report on Form 10-K for the year
ended December 31, 2006, as filed with the Securities and Exchange
Commission. Lexicon undertakes no obligation to update or revise
any such forward-looking statements, whether as a result of new
information, future events or otherwise. DATASOURCE: Lexicon
Pharmaceuticals, Inc. CONTACT: Bobbie Faulkner, Manager, Investor
Relations of Lexicon Pharmaceuticals, Inc., +1-281-863-3503, Web
site: http://www.lexpharma.com/
Copyright
Lexicon Pharmaceuticals (NASDAQ:LXRX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Lexicon Pharmaceuticals (NASDAQ:LXRX)
Historical Stock Chart
From Jul 2023 to Jul 2024